FDA inspectors have come down hard on a drugmaker in Taiwan, issuing a warning letter to Taiwan Three Mast Pharmaceutical in Tainan City for serious manufacturing violations.
India, a country forging its way into the vaccine production business, has found itself descending into the clutches of its private sector.
Medtronic's executives will devote their energies in 2013 to M&A, accelerating the company's global expansion and adjusting to the U.S. health reform law, CEO Omar Ishrak told a standing-room-only crowd at the J.P. Morgan Healthcare Conference in San Francisco early Monday.
With generous tax laws, incentives and a location ideal for servicing Southeast Asia, Malaysia is drawing new plants from manufacturers looking to expand in those markets.
The clamor for reform of India's clinical trial regulations has reached a fever pitch over the past year, and now the country's Supreme Court is ordering the Health Ministry to keep a close eye on applications for new studies.
Russia is tightening the screws on foreign drugmakers. Already under orders to partner up with domestic companies and establish local production facilities, global pharma companies will now be squeezed out of state purchasing deals.
India's clinical trial regulations (or lack thereof) have long been the subject of international debate, and now the country's National Commission for Protection of Child Rights is looking to enact standardized rules for trials on children, saying many are subjected to studies without their parents being made aware.
WuXi PharmaTech and PRA are joining forces to launch an independent CRO in China, combining their capacities in the country to create a jointly owned venture for Phase I-IV clinical trial services.
After months of rumors, ShangPharma is pulling the trigger on a deal that will take it private, creating a parent company that unites private equity firms and some of the CRO's leadership.
Sony and Olympus made headlines in September when they announced plans to partner and develop medical devices, but those ambitions will have to wait for next year as the two face a delay over anti-trust sign-offs.